According to data and analytics company, GlobalData, new real-world evidence will support the use of a biosimilar treatment for Crohn’s disease (CD), leading to a boost in the biosimilar market value.
intestines
This prediction has been made after the 12-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) were presented at the 13th Congress of the European Crohn’s and Colitis Organization (ECCO). The results from this study demonstrated the comparable efficacy of Celltrion’s CT-P13 (infliximab biosimilar) to the reference product — Johnson and Johnson’s Remicade (infliximab) — as well as AbbVie’s Humira (adalimumab).